Pharmaceutical - Victoza, Boehringer Ingelheim

Filter

Popular Filters

EU regulator finds no added pancreatic risks for GLP-1 diabetes drugs

26-07-2013

Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbBydureonDiabetesEli LillyEuropeJanuviaMerck & CoNovo NordiskOnglyzaPharmaceuticalRegulationTradjentaVictoza

Lilly and Boehringer Ingelheim's basal insulin MAA accepted by EMA

08-07-2013

US drug major Eli Lilly (NYSE: LLY) and family-owned German pharma firm Boehringer Ingelheim today (July…

Boehringer IngelheimDiabetesEli LillyLantusNovo NordiskPharmaceuticalSanofiVictoza

Highlights of American Diabetes Association meeting

11-06-2012

The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

Back to top